Trump unveils 'American Patients First' plan to bring down drug costs 

White House
The White House has unveiled its drug pricing plan. (Pixabay)

President Donald Trump has unveiled the administration's policy plan to tackle the rising cost of drugs: "American Patients First." 

Trump called the proposal "the most sweeping action in history to lower the price of prescription drugs for the American people" at an event to mark the release of the blueprint (PDF). 

The plan, he said, focuses on four central goals:

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.
  1. Increasing competition.
  2. Easing negotiation.
  3. Creating incentives to lower prices.
  4. Lowering out-of-pocket spending on drugs.

The plan includes actions the administration may take immediately and those that the White House is considering; it is seeking feedback on these elements from stakeholders. The Food and Drug Administration will begin acting quickly to bring more generics and biosimilars to the market to address competition issues, for example.

The administration plans to pursue ways to encourage sharing samples of generics and education on biosimilars to encourage more physicians to promote them. 

RELATED: CMS mulls new payment models for drug pricing 

Senior administration officials said Thursday night that Trump would not pursue plans to negotiate directly with pharmaceutical companies through Medicare, a proposal that Democrats have touted. 

Instead, "American Patients First" calls for reforms in Medicare Part D to allow plan sponsors to negotiate lower prices for high-cost drugs, including negotiation tools that may be available to private payers. The administration also plans to address incentives in Part D to push drug companies to lower prices.

"There's a big incentive to do that," Trump said. "And we will not reward companies constantly raise prices."

The plan builds on elements included the president's budget proposal for fiscal year 2019, which includes a five-part plan to restructure the Part D program to reduce drug costs. The budget includes proposals to cap spending in Medicare Part B and move Part B coverage into Part D to facilitate better negotiation. 

Another area of particular focus is "foreign freeloading." The U.S. pays for 70% of the profits of branded drugs among OECD countries because many have government-run health systems that pay one price for drugs, senior administration officials said.

Trump said this leads American patients to subsidize the costs of medical research and development for other countries. 

"You can look at some of the countries, their medicine is a tiny fraction of what the medicine costs in the USA," Trump said. "It's unfair and it's ridiculous and it's not gonna happen any longer." 

RELATED: Brand name drug prices grew 10 times faster than inflation over last 5 years, report finds  

The White House already outlined a number of proposals for reducing drug prices through a report from the Council of Economic Advisers. In that report, the administration pushed for pharmacy benefit managers to share rebates directly with consumers. 

"We are very much eliminating the middlemen," Trump said. "The middlemen became very, very rich. … They won't be so rich now."

Department of Health and Human Services Secretary Alex Azar said that the administration would not propose "cheap political gimmicks" and was instead focused on a "sophisticated" approach centered on fostering competition in the private sector. 

"American Patients First" is the "most comprehensive action plan for drug affordability of any president in our history," Azar said. 

Azar reiterated the agency's focus on price transparency and said that was another crucial element of the drug pricing plan. The FDA, for example, is going to immediately begin to examine ways to push drug companies to disclose prices in their advertising.